-
1
-
-
0037831023
-
The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)
-
National Comorbidity Survey Replication, PubMed. doi:10.1001/jama.289.23.3095
-
Kessler RC, Berglund P, Demler O, et al, National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. PubMed doi:10.1001/jama.289.23.3095
-
(2003)
JAMA
, vol.289
, Issue.23
, pp. 3095-3105
-
-
Kessler, R.C.1
Berglund, P.2
Demler, O.3
-
2
-
-
34548396844
-
Depression, chronic diseases, and decrements in health: Results from the World Health Surveys
-
PubMed. doi:10.1016/S0140-6736(07)61415-9
-
Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858. PubMed doi:10.1016/S0140-6736(07)61415-9
-
(2007)
Lancet
, vol.370
, Issue.9590
, pp. 851-858
-
-
Moussavi, S.1
Chatterji, S.2
Verdes, E.3
-
3
-
-
0031001720
-
Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study
-
PubMed. doi:10.1016/S0140-6736(96)07492-2
-
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 1997;349(9064):1498-1504. PubMed doi:10.1016/S0140-6736(96)07492-2
-
(1997)
Lancet
, vol.349
, Issue.9064
, pp. 1498-1504
-
-
Murray, C.J.1
Lopez, A.D.2
-
4
-
-
34547534646
-
Safety and tolerability of antidepressants: Weighing the impact on treatment decisions
-
PubMed
-
Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):26-34. PubMed
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.SUPPL 8
, pp. 26-34
-
-
Schatzberg, A.F.1
-
5
-
-
0029967073
-
Definition and epidemiology of treatment-resistant depression
-
PubMed. doi:10.1016/S0193-953X(05)70283-5
-
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200. PubMed doi:10.1016/S0193-953X(05)70283-5
-
(1996)
Psychiatr Clin North Am
, vol.19
, Issue.2
, pp. 179-200
-
-
Fava, M.1
Davidson, K.G.2
-
6
-
-
30044433660
-
STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
-
PubMed. doi:10.1176/appi.ajp.163.1.28
-
Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. PubMed doi:10.1176/appi.ajp.163.1.28
-
(2006)
Am J Psychiatry
, vol.163
, Issue.1
, pp. 28-40
-
-
Trivedi, M.H.1
Rush, A.J.2
Wisniewski, S.R.3
-
7
-
-
43949153474
-
Contemporary management of depression
-
PubMed. doi:10.1016/0002-9343(94)90360-3
-
Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med. 1994;97(6A):24S-32S. PubMed doi:10.1016/0002-9343(94)90360-3
-
(1994)
Am J Med
, vol.97
, Issue.6 A
-
-
Andrews, J.M.1
Nemeroff, C.B.2
-
8
-
-
0036261230
-
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis
-
PubMed. doi:10.1192/bjp.180.5.396
-
Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180(5):396-404. PubMed doi:10.1192/bjp.180.5.396
-
(2002)
Br J Psychiatry
, vol.180
, Issue.5
, pp. 396-404
-
-
Smith, D.1
Dempster, C.2
Glanville, J.3
-
9
-
-
0035111499
-
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
-
PubMed. doi:10.1192/bjp.178.3.234
-
Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178(3):234-241. PubMed doi:10.1192/bjp.178.3.234
-
(2001)
Br J Psychiatry
, vol.178
, Issue.3
, pp. 234-241
-
-
Thase, M.E.1
Entsuah, A.R.2
Rudolph, R.L.3
-
10
-
-
34447337808
-
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
-
PubMed. doi:10.1097/YIC.0b013e32821c6189
-
Shelton RC, Andorn AC, Mallinckrodt CH, et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol. 2007;22(6):348-355. PubMed doi:10.1097/YIC.0b013e32821c6189
-
(2007)
Int Clin Psychopharmacol
, vol.22
, Issue.6
, pp. 348-355
-
-
Shelton, R.C.1
Andorn, A.C.2
Mallinckrodt, C.H.3
-
11
-
-
0036829053
-
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
-
PubMed. doi:10.1016/S0022-3956(02)00060-2
-
Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6):383-390. PubMed doi:10.1016/S0022-3956(02)00060-2
-
(2002)
J Psychiatr Res
, vol.36
, Issue.6
, pp. 383-390
-
-
Detke, M.J.1
Lu, Y.2
Goldstein, D.J.3
-
12
-
-
0036257156
-
The psychopharmacology of painful physical symptoms in depression
-
PubMed
-
Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002;63(5):382-383. PubMed
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.5
, pp. 382-383
-
-
Stahl, S.M.1
-
13
-
-
0035570622
-
Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response
-
PubMed
-
Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001;26(suppl):S3-S10. PubMed
-
(2001)
J Psychiatry Neurosci
, vol.26
, Issue.SUPPL
-
-
Blier, P.1
-
14
-
-
58849155238
-
-
Philadelphia, PA: Wyeth Pharmaceuticals Inc
-
Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2008.
-
(2008)
Pristiq [package insert]
-
-
-
15
-
-
70349344956
-
-
Indianapolis, IN: Eli Lilly and Company
-
Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.
-
(2007)
Cymbalta [package insert]
-
-
-
16
-
-
78650563092
-
-
Philadelphia, PA: Wyeth Pharmaceuticals Inc
-
Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2006.
-
(2006)
Effexor XR [package insert]
-
-
-
17
-
-
54449099975
-
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
-
PubMed. doi:10.1097/YIC.0b013e32830cebed
-
Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243-253. PubMed doi:10.1097/YIC.0b013e32830cebed
-
(2008)
Int Clin Psychopharmacol
, vol.23
, Issue.5
, pp. 243-253
-
-
Boyer, P.1
Montgomery, S.2
Lepola, U.3
-
18
-
-
34249743293
-
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder
-
PubMed. doi:10.4088/JCP.v68n0504
-
DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677-688. PubMed doi:10.4088/JCP.v68n0504
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.5
, pp. 677-688
-
-
DeMartinis, N.A.1
Yeung, P.P.2
Entsuah, R.3
-
19
-
-
47949131252
-
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
-
PubMed. doi:10.1185/03007990802161923
-
Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877-1890. PubMed doi:10.1185/03007990802161923
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.7
, pp. 1877-1890
-
-
Liebowitz, M.R.1
Manley, A.L.2
Padmanabhan, S.K.3
-
20
-
-
34948830614
-
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder
-
PubMed. doi:10.1097/YIC.0b013e3281e2c84b
-
Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338-347. PubMed doi:10.1097/YIC.0b013e3281e2c84b
-
(2007)
Int Clin Psychopharmacol
, vol.22
, Issue.6
, pp. 338-347
-
-
Septien-Velez, L.1
Pitrosky, B.2
Padmanabhan, S.K.3
-
21
-
-
66849098031
-
An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder
-
PubMed
-
Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144-154. PubMed
-
(2009)
CNS Spectr
, vol.14
, Issue.3
, pp. 144-154
-
-
Thase, M.E.1
Kornstein, S.G.2
Germain, J.M.3
-
22
-
-
33745958408
-
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor
-
PubMed. doi:10.1124/jpet.106.103382
-
Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657-665. PubMed doi:10.1124/jpet.106.103382
-
(2006)
J Pharmacol Exp Ther
, vol.318
, Issue.2
, pp. 657-665
-
-
Deecher, D.C.1
Beyer, C.E.2
Johnston, G.3
-
23
-
-
12844267437
-
Duloxetine: A dual reuptake inhibitor
-
PubMed. doi:10.1345/aph.1E084
-
Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. Ann Pharmacother. 2004;38(12):2078-2085. PubMed doi:10.1345/aph.1E084
-
(2004)
Ann Pharmacother
, vol.38
, Issue.12
, pp. 2078-2085
-
-
Dugan, S.E.1
Fuller, M.A.2
-
24
-
-
55949086841
-
An assessment of drug-drug interactions: The effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects
-
PubMed. doi:10.1124/dmd.108.021527
-
Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. PubMed doi:10.1124/dmd.108.021527
-
(2008)
Drug Metab Dispos
, vol.36
, Issue.12
, pp. 2484-2491
-
-
Patroneva, A.1
Connolly, S.M.2
Fatato, P.3
-
25
-
-
78650567891
-
Desvenlafaxine succinate, venlafaxine, duloxetine, paroxetine, sertraline, and bupropion: Comparing inhibitory effects on human cytochrome P450 and P-glycoprotein activities
-
Poster presented at the, October 22-26, Rio Grande, Puerto Rico
-
Oganesian A, Shilling A, Young-Sciame R, et al. Desvenlafaxine succinate, venlafaxine, duloxetine, paroxetine, sertraline, and bupropion: comparing inhibitory effects on human cytochrome P450 and P-glycoprotein activities. Poster presented at the 14th North American International Society for the Study of Xenobiotics Meeting; October 22-26, 2006; Rio Grande, Puerto Rico.
-
(2006)
14th North American International Society for the Study of Xenobiotics Meeting
-
-
Oganesian, A.1
Shilling, A.2
Young-Sciame, R.3
-
26
-
-
68749112734
-
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies
-
PubMed. doi:10.1016/j.clinthera.2009.07.006
-
Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31(pt 1):1405-1423. PubMed doi:10.1016/j.clinthera.2009.07.006
-
(2009)
Clin Ther
, vol.31
, Issue.PT 1
, pp. 1405-1423
-
-
Tourian, K.A.1
Padmanabhan, S.K.2
Groark, J.3
-
27
-
-
0004235298
-
-
American Psychiatric Association, Fourth Edition. Washington, DC: American Psychiatric Association
-
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
-
(1994)
Diagnostic and Statistical Manual of Mental Disorders
-
-
-
28
-
-
72949151592
-
A rating scale for depression
-
PubMed. doi:10.1136/jnnp.23.1.56
-
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMed doi:10.1136/jnnp.23.1.56
-
(1960)
J Neurol Neurosurg Psychiatry
, vol.23
, Issue.1
, pp. 56-62
-
-
Hamilton, M.1
-
29
-
-
0003586259
-
-
Guy W, ed., US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health
-
Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health;1976:218-222.
-
(1976)
ECDEU Assessment Manual for Psychopharmacology
, pp. 218-222
-
-
-
30
-
-
0018425438
-
A new depression scale designed to be sensitive to change
-
PubMed. doi:10.1192/bjp.134.4.382
-
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. PubMed doi:10.1192/bjp.134.4.382
-
(1979)
Br J Psychiatry
, vol.134
, Issue.4
, pp. 382-389
-
-
Montgomery, S.A.1
Asberg, M.2
-
31
-
-
0032421570
-
The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
-
quiz 34-57. PubMed
-
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.SUPPL 20
, pp. 22-33
-
-
Sheehan, D.V.1
Lecrubier, Y.2
Sheehan, K.H.3
-
32
-
-
66849093926
-
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder
-
PubMed
-
Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183-195. PubMed
-
(2009)
CNS Spectr
, vol.14
, Issue.4
, pp. 183-195
-
-
Clayton, A.H.1
Kornstein, S.G.2
Rosas, G.3
-
33
-
-
78650567269
-
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
-
Accessed May 4, 2010
-
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Medical Dictionary for Regulatory Activities. http://www.meddramsso.com/index.asp. Accessed May 4, 2010.
-
Medical Dictionary for Regulatory Activities
-
-
-
34
-
-
30044439200
-
Continuity of antidepressant treatment for adults with depression in the United States
-
PubMed. doi:10.1176/appi.ajp.163.1.101
-
Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101-108. PubMed doi:10.1176/appi.ajp.163.1.101
-
(2006)
Am J Psychiatry
, vol.163
, Issue.1
, pp. 101-108
-
-
Olfson, M.1
Marcus, S.C.2
Tedeschi, M.3
-
35
-
-
0037130645
-
Discontinuation of use and switching of antidepressants: Influence of patient-physician communication
-
PubMed. doi:10.1001/jama.288.11.1403
-
Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409. PubMed doi:10.1001/jama.288.11.1403
-
(2002)
JAMA
, vol.288
, Issue.11
, pp. 1403-1409
-
-
Bull, S.A.1
Hu, X.H.2
Hunkeler, E.M.3
-
37
-
-
33746253361
-
Duloxetine in the treatment of major depressive disorder: Comparisons of safety and tolerability in male and female patients
-
doi:10.1016/j.jad.2006.04.006 PubMed
-
Stewart DE, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord. 2006;94(1-3):183-189. doi:10.1016/j.jad.2006.04.006 PubMed
-
(2006)
J Affect Disord
, vol.94
, Issue.1-3
, pp. 183-189
-
-
Stewart, D.E.1
Wohlreich, M.M.2
Mallinckrodt, C.H.3
|